跳至主要内容

Medicilon Pharmacological Model Service

 After 13 years of accumulation, Medicilon has now completed the establishment of more than 200 tumor animal models. At the same time, Medicilon’s pharmacological team has also established 50 in the fields of digestive system, metabolic diseases, central nervous system and immune inflammation. A variety of animal models are available for customers to choose from. Medicilon’s pharmacodynamic animal model was developed under the cooperation of Medicilon and MPI Research and passed AAALAC certification and conformed to the multinational GLP standard animal room environment. After that, it has been verified by various parties under the independent leadership of Medicilon’s expert team. Tested, the number and category of completion have been steadily increasing year by year. So far, it has been highly recognized by many customers in the industry and has formed a complete medicinal animal model library.

Medicilon can provide various animal models (including renal failure model, anemia animal model, gastric acid secretion animal model, and gastric ulcer model) to test drug effectiveness according to client needs. We can conduct tests on typical digestive system diseases, including gastric acid secretions, gastric ulcers, and renal failure, using rats as subjects.

Now that Medicilon’s pharmacodynamic team has joined Dr. Wenxin Dong. Dr. Dong has profound knowledge in the fields of depression, Alzheimer’s, pain, anxiety, Parkinson’s disease, etc. I believe that with Dr. Dong’s joining, Medicilon’s efficacy In terms of service, a more satisfactory answer sheet will be delivered.

Pharmacological Model Service-576x324.png

Medicilon drug efficacy animal model and case sharing

Digestive system and other disease models
◇ Kidney failure
Rat nephrectomy (5/6) model
Detect
Blood and urine biochemical indicators, pathology
◇ Anemia
Anemia model induced by renal failure in rats
Detect
Blood and urine biochemical indicators, hematology indicators, pathology, hematology smears
◇ Stomach ulcer
1. Gastric acid secretion model:
Pyloric ligation gastric acid secretion model
Histamine gastric acid secretion model
2. Gastric ulcer model:
Ethanol gastric ulcer model
Gastric ulcer model induced by non-steroidal anti-inflammatory drugs
Gastric ulcer model caused by cold water stress
Acetic acid chronic gastric ulcer model
Detect
Gastric acidity, ulcers, pathology
Experience of successful FDA/CFDA application for multiple new drugs —Develop R&D strategies for customers

Case

Cardiovascular and metabolic disease models
◇ Obesity and diabetes
● Streptozotocin induces diabetes (large/mouse)
● Spontaneous diabetic mice db/db, ob/ob
● ZDF in spontaneous diabetic rats
● Diabetic obese mice induced by high-fat and high-sugar diet
Detect
● Fasting blood glucose
● Urine glucose, glycosylated hemoglobin, blood biochemical indicators
● Glucose tolerance test (oral, intraperitoneal or intravenous injection)
● Food intake, weight
● Insulin resistance and sensitivity
◇ Hyperuricemia
● Hyperuricemia induced by potassium oxazine
Detect
● Blood uric acid index
◇ Liver fibrosis
● Bile duct ligation
● TAA-induced liver fibrosis
Compound factor method inducing rat liver fibrosis model
ConA-induced liver fibrosis in mice
Pig serum-induced liver fibrosis model in rats
Detect
● Liver function indicators
● Liver pathological staining (HE, Masson staining)
◇ Dyslipidemia
● High-fat/cholesterol/fructose diet induces hyperlipidemia hamster model
● APOE mice with hereditary atherosclerosis
◇ Non-alcoholic fatty liver model
● APOE mice with hereditary atherosclerosis
Rat nonalcoholic fatty liver
Detect
● Blood lipid biochemical indicators
● Liver and artery pathology
◇ Thrombosis model
● Arteriovenous bypass thrombosis
Tail vein thrombosis induced by carrageenan in mice
Rat deep vein thrombosis
● Carotid artery thrombosis

Case

Central Nervous System Disease Model
◇ Anti-depressant
● Inhibition of 5-HT, NA, DA uptake by brain synaptosomes (sample screening, IC50 determination)
Forced swimming test (big/mouse, Noduls software, video analysis)
● Mouse tail suspension test (Noduls software, video analysis)
● Serotonin enhancement test
● Reserpine-induced ptosis test
● Yohimbine toxicity enhancement test
High-dose apomorphine antagonism
Chronic mild unpredictable irritation (CUMS) model in rats
Determination of the activity of monoamine oxidase MAO-A and MAO-B in mouse brain
Protective effects on hippocampal nerve cells of newborn rats (glutamate injury, hydrogen peroxide injury, hypoglycemia and hypoxia injury, dexamethasone injury, etc.)
Effect on SH-SY5Y cell synthesis and secretion of BDNF
◇ Anticonvulsant
● Yohimbine toxicity enhancement test
● Pentylenetetrazol convulsion
● Bicuculline convulsion
● Pytoxin convulsion
◇ Calm, hypnotic and anti-anxiety
● Synergistic effect with pentobarbital drugs
● Effect on subthreshold hypnotic dose of barbital
● Sleep again test
● Open field experiment (big/mouse, full camera monitoring, software processing)
Elevated plus maze method for rats (full camera monitoring, software processing)
Rat shuttle box method (full camera monitoring, software processing)
◇ Pain (with von Frey hairs test)
● Hot plate method
● Flick method
● Thermal radiation pain method
Tenderness
● Acetic acid writhing method
● Formalin pain method
● Pain caused by the adjuvant CFA
● Carrageenan pain model
● LPS-induced pain model
● Selective spinal nerve ligation (L5/L6)
● Selective injury model of sciatic nerve branch (SNI)
● Diabetes pain
◇ Anti-dementia
Mouse Acquired Memory Impairment Model (6-channel mouse platform video analysis system)
Mouse model of poor memory consolidation (6 channels of mouse jumping platform video analysis system)
Mouse memory reproduction disorder model (6 channels of mouse avoiding dark visual screen analysis system)
? Mouse light and dark box method (4-channel mouse light and dark box visual screen analysis system)
Rat model of acquired memory impairment (Morris water maze video analysis system)
Determination of Acetylcholinesterase Activity in Mouse Brain
D-galactose-induced mouse dementia model (Morris water maze visual screen analysis system spatial memory function test, mouse brain SOD activity, MDA content determination)
APP/PS1 double transgenic mouse model: including:
Morris water maze visual screen analysis system spatial memory function test
Mouse brain immunohistochemical staining, detection: AB precipitation, phosphorylated Tau protein, BDNF content
Mouse brain related inflammatory factors detection
Related molecular biology tests
In vitro experiments
Inhibition of Aβ aggregation test
Injury model of Aβ on hippocampal cells of newborn rats cultured in vitro
Hydrogen peroxide damage model of rat hippocampal cells cultured in vitro

◇ Anti-schizophrenia
Positive symptoms of schizophrenia caused by MK801
Negative symptoms of schizophrenia caused by MK801
Negative symptoms of schizophrenia caused by ketamine
Rat stiffness test
Rat Lower Lip Retraction Test
◇ Anti-anxiety
◇ Anti-Parkinson’s disease 6-hydroxydopamine-induced rat Parkinson’s disease model
MPTP model (PD model with bilateral damage)
Oxytremorine-induced tremor model

Inflammation and immune system disease models
◇ Arthritis
● Rheumatoid arthritis CIA mouse/rat model
● Rat arthritis model induced by AIA adjuvant
● EAE experimental allergic encephalomyelitis mouse model
◇ Psoriasis
● Mouse psoriasis model induced by imiquimod
Detect
● Evaluation of clinical indicators
● Detection of inflammatory factors
● Pathology
◇ Acute inflammation

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati